(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
@ $6.41
发出时间: 15 Feb 2024 @ 03:41
回报率: -25.97%
上一信号: Feb 15 - 02:57
上一信号:
回报率: 2.72 %
Live Chart Being Loaded With Signals
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology...
Stats | |
---|---|
今日成交量 | 3.88M |
平均成交量 | 2.47M |
市值 | 705.24M |
EPS | $0 ( 2024-03-11 ) |
下一个收益日期 | ( $-0.180 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.65 |
ATR14 | $0.0100 (0.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-26 | Summer Road Llc | Buy | 930 851 | Common Stock, $0.0001 par value per share |
2024-02-22 | Dugel Pravin | Buy | 1 282 469 | Stock Option (Right to Buy) |
2024-02-22 | Dugel Pravin | Buy | 854 979 | Common Stock |
2024-02-22 | Nayak Sanjay | Buy | 244 550 | Stock Option (Right to Buy) |
2024-02-22 | Nayak Sanjay | Buy | 80 300 | Common Stock |
INSIDER POWER |
---|
97.80 |
Last 98 transactions |
Buy: 9 847 283 | Sell: 256 052 |
音量 相关性
Ocular Therapeutix Inc 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Ocular Therapeutix Inc 相关性 - 货币/商品
Ocular Therapeutix Inc 财务报表
Annual | 2023 |
营收: | $58.44M |
毛利润: | $53.16M (90.96 %) |
EPS: | $-1.010 |
FY | 2023 |
营收: | $58.44M |
毛利润: | $53.16M (90.96 %) |
EPS: | $-1.010 |
FY | 2022 |
营收: | $51.49M |
毛利润: | $46.95M (91.18 %) |
EPS: | $-0.830 |
FY | 2021 |
营收: | $43.52M |
毛利润: | $39.12M (89.88 %) |
EPS: | $-0.0900 |
Financial Reports:
No articles found.
Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。